专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2014139836A1 PHARMACEUTICAL COMPOSITIONS COMPRISING IMATINIB 审中-公开
标题翻译：包含IMATINIB的药物组合物
公开(公告)号：WO2014139836A1
公开(公告)日：2014-09-18
申请号：PCT/EP2014/054173
申请日：2014-03-04
申请人： PHARMACEUTICAL ORIENTED SERVICES LTD , REMEDICA LTD
发明人： PATTIHIS, Charalambos , NORDMANN, Antje , PANAGOPOULOS, Panagiotis , PANITSAS, Konstantinos-Emmanouil
IPC分类号： A61K9/20 , A61K31/506
CPC分类号： A61K31/506 , A61K9/2009 , A61K9/2054
摘要： The present invention is concerned with a solid oral dosage form comprising imatinib, or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable excipients, said solid oral dosage form comprising said imatinib in an amount of greater than about 80% based on the weight of imatinib free base compared to the total weight of said solid oral dosage form.
摘要翻译：本发明涉及包含伊马替尼或其药学上可接受的盐以及一种或多种药学上可接受的赋形剂的固体口服剂型，所述固体口服剂型包含所述伊马替尼的量大于约80％，基于伊马替尼游离碱的重量与所述固体口服剂型的总重量相比。

2. 发明申请

WO2013139826A1 PHARMACEUTICAL COMPOSITIONS COMPRISING IMATINIB 审中-公开
标题翻译：包含IMATINIB的药物组合物
公开(公告)号：WO2013139826A1
公开(公告)日：2013-09-26
申请号：PCT/EP2013/055764
申请日：2013-03-20
申请人： REMEDICA LTD , PHARMACEUTICAL ORIENTED SERVICES LTD , PATTIHIS, Charalambos , NORDMANN, Antje , PANAGOPOULOS, Panagiotis , PANITSAS, Konstantinos-Emmanouil
发明人： PATTIHIS, Charalambos , NORDMANN, Antje , PANAGOPOULOS, Panagiotis , PANITSAS, Konstantinos-Emmanouil
IPC分类号： A61K31/506 , A61K47/38 , A61K9/16 , A61K9/20
CPC分类号： A61K31/506 , A61K9/2077 , A61K9/2866
摘要： The present invention is concerned with a solid oral dosage form comprising imatinib, or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable excipients, said solid oral dosage form comprising said imatinib in an amount in the range of about 27.0 to 29.0% based on the weight of imatinib free base compared to the total weight of said solid oral dosage form.
摘要翻译：本发明涉及包含伊马替尼或其药学上可接受的盐以及一种或多种药学上可接受的赋形剂的固体口服剂型，所述固体口服剂型包含所述伊马替尼的量为约27.0至29.0％基于伊马替尼游离碱的重量与所述固体口服剂型的总重量相比。

3. 发明申请

WO2019219823A1 SOLID DISPERSION CONTAINING RITONAVIR 审中-公开
公开(公告)号：WO2019219823A1
公开(公告)日：2019-11-21
申请号：PCT/EP2019/062639
申请日：2019-05-16
申请人： PHARMACEUTICAL ORIENTED SERVICES LTD. , REMEDICA LTD
发明人： PANAGOPOULOS, Panagiotis , PANITSAS, Konstantinos-Emmanouil , KOMPOROZOS, Konstantinos , LIKOUDIS, Aggelos , SYRIGOS, Matthaios , HATZOULI, Maria , PATTIHIS, Charalambos , NORDMANN, Antje , NEOPTOMEMOU, Michalis
IPC分类号： A61K9/20 , A61K9/16 , A61K9/24 , A61K31/427
摘要： The present invention relates to a solid dispersion containing ritonavir and a cationic polymer, and to the use of the solid dispersion for the preparation of a pharmaceutical composition for oral administration, which is preferably a tablet. The pharmaceutical composition is intended for the treatment of HIV and may additionally contain a HIV protease inhibitor selected from darunavir, lopinavir, atazanavir, tipranavir and saquinavir.

4. 发明申请

WO2020126017A1 DOSAGE FORM CONTAINING ABIRATERONE ACETATE 审中-公开
公开(公告)号：WO2020126017A1
公开(公告)日：2020-06-25
申请号：PCT/EP2018/086401
申请日：2018-12-20
申请人： PHARMACEUTICAL ORIENTED SERVICES LTD , REMEDICA LTD
发明人： PANAGOPOULOS, Panagiotis , PANITSAS, Konstantinos-Emmanouil , ALEXAKI, Pandora , KANTAS, Dimosthenis , VACHRATIDIS, George , VOUVALIDIS, John , MICHALI, Christina , PATTIHIS, Charalambos , NORDMANN, Antje , NEOPTOLEMOU, Michalis
IPC分类号： A61K9/20 , A61K31/58
摘要： The present invention relates to a solid unit dosage form for oral administration, preferably, a tablet, containing abiraterone acetate, whereby the solid unit dosage form is prepared by wet-granulation. The solid unit dosage form is intended for the treatment of prostate cancer.

5. 发明申请

WO2017144109A1 DASATINIB FORMULATION 审中-公开
标题翻译： DASATINIB配方
公开(公告)号：WO2017144109A1
公开(公告)日：2017-08-31
申请号：PCT/EP2016/054037
申请日：2016-02-25
申请人： REMEDICA LTD , PHARMACEUTICAL ORIENTED SERVICES LTD
发明人： PATTIHIS, Charalambos , NORDMANN, Antje , PANAGOPOULOS, Panagiotis , PANITSAS, Konstantinos-Emmanouil , ALEXAKI, Pandora , KATAKALOU, Christina , VIDALIS, Matthew , KATHIOTOU, Georgia
IPC分类号： A61K9/16 , A61K9/20 , A61K31/506 , A61P35/02
CPC分类号： A61K9/2054 , A61K9/16 , A61K9/1652 , A61K31/506
摘要： The present invention relates to an oral dosage form comprising dasatinib, or a pharmaceutically acceptable salt thereof. In particular, the present invention relates to an oral dosage form comprising dasatinib, or a pharmaceutically acceptable salt thereof, wherein the amount of disintegrant present is controlled so as to provide desirable dissolution and / or pharmacokinetic profiles.
摘要翻译：本发明涉及包含达沙替尼或其药学上可接受的盐的口服剂型。具体而言，本发明涉及包含达沙替尼或其药学上可接受的盐的口服剂型，其中控制存在的崩解剂的量以提供期望的溶解和/或药代动力学特征。

6. 发明申请

WO2015169932A1 POLYMORPH PURITY, MONITORING AND ASSOCIATED COMPOSITIONS 审中-公开
标题翻译： POLYMORPH纯度，监测和相关组合物
公开(公告)号：WO2015169932A1
公开(公告)日：2015-11-12
申请号：PCT/EP2015/060129
申请日：2015-05-07
申请人： PHAROS GENERICS LTD , REMEDICA LTD
IPC分类号： C07D239/94 , G01N23/20 , A61K31/517 , A61P35/00
CPC分类号： C07D239/94 , G01N23/20 , G01N2223/62
摘要： The present invention relates to erlotinib hydrochloride Form A that includes no detectable erlotinib hydrochloride Form B; as determined by X-ray powder diffraction analysis that includes a differentiation resolution and a 2-theta scan region that enables detection of the absence, or presence, of a characteristic 2-theta peak of eriotinib hydrochloride Form B in the region of 6.0 to 6.4 degrees 2-theta. There is also provided a pharmaceutical composition comprising the same. Furthermore, a composition according to the invention can be further characterized by a stability profile whereby on storage at (i) a temperature of at least about 23°C, (ii) a relative humidity of at least about 55%, and (iii) for a period of at least about 6 months, no erlotinib hydrochloride Form B is detectable by X-ray powder diffraction analysis.
摘要翻译：本发明涉及不含可检测的盐酸埃罗替尼形式B的盐酸埃罗替尼形式A; 如通过X射线粉末衍射分析确定的，其包括分辨分辨率和2-θ扫描区域，其能够检测6.0至6.4范围内的盐酸埃替替韦形式B的特征2-θ峰的存在或不存在度2-θ。还提供了包含其的药物组合物。此外，根据本发明的组合物可以进一步的特征在于稳定性曲线，其在（i）至少约23℃的温度，（ii）至少约55％的相对湿度，和（iii）至少约6个月的时间，通过X射线粉末衍射分析可以检测到盐酸埃罗替尼形式B。

7. 发明专利

SG11202107948PA DOSAGE FORM CONTAINING ABIRATERONE ACETATE 未知
公开(公告)号：SG11202107948PA
公开(公告)日：2021-08-30
申请号：SG11202107948P
申请日：2018-12-20
申请人： PHARMACEUTICAL ORIENTED SERVICES LTD , REMEDICA LTD
发明人： PANAGOPOULOS PANAGIOTIS , PANITSAS KONSTANTINOS-EMMANOUIL , ALEXAKI PANDORA , KANTAS DIMOSTHENIS , VACHRATIDIS GEORGE , VOUVALIDIS JOHN , MICHALI CHRISTINA , PATTIHIS CHARALAMBOS , NORDMANN ANTJE , NEOPTOLEMOU MICHALIS
IPC分类号： A61K9/20 , A61K31/58
摘要： The present invention relates to a solid unit dosage form for oral administration, preferably, a tablet, containing abiraterone acetate, whereby the solid unit dosage form is prepared by wet-granulation. The solid unit dosage form is intended for the treatment of prostate cancer.

8. 发明专利

GB201204810D0 Pharmaceutical compositions 未知
公开(公告)号：GB201204810D0
公开(公告)日：2012-05-02
申请号：GB201204810
申请日：2012-03-20
申请人： PHAROS PHARMACEUTICAL ORIENTED SERVICES LTD , REMEDICA LTD

9. 发明专利

MX2016014531A PUREZA POLIMORFICA, MONITOREO Y COMPOSICIONES ASOCIADAS. 未知
公开(公告)号：MX2016014531A
公开(公告)日：2017-05-01
申请号：MX2016014531
申请日：2015-05-07
申请人： REMEDICA LTD
发明人： CHARALAMBOS PATTIHIS , ANTJE NORDMANN
IPC分类号： C07D239/94 , A61K31/517 , A61P35/00 , G01N23/20
摘要： La presente invención se refiere a la forma A del clorhidrato de erlotinib que no incluye ninguna forma B de clorhidrato de erlotinib detectable; como se determina por el análisis de difracción por rayos X mediante polvos que incluye una resolución de diferenciación y una región de exploración 2-teta que permite la detección de la ausencia o presencia de un pico 2-teta característico de la forma B del clorhidrato de erlotinib en la región 2-teta de 6.0 a 6.4 grados. También se proporciona una composición farmacéutica que comprende la misma. Además, una composición de acuerdo con la invención puede caracterizarse adicionalmente por un perfil de estabilidad, por el cual con el almacenamiento a (i) una temperatura de al menos aproximadamente 23°C, (ii) una humedad relativa de al menos aproximadamente 55%, y (iii) durante un periodo de al menos aproximadamente 6 meses, la Forma B de clorhidrato de erlotinib no es detectable por análisis de difracción por rayos X mediante polvos.

10. 发明专利

GB201408094D0 Polymorph purity, monitoring and associated compositions 未知
公开(公告)号：GB201408094D0
公开(公告)日：2014-06-18
申请号：GB201408094
申请日：2014-05-07
申请人： PHAROS GENERICS LTD , REMEDICA LTD

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式